bivalent hpv vaccine outshines quadrivalent vaccine?

PharmacoEconomics & Outcomes News 624 - 19 Mar 2011 Bivalent HPV vaccine outshines quadrivalent vaccine? In Italy, a bivalent human papillomavirus (HPV) vaccine may be associated with a greater reduction in precancerous and cervical cancer lesions than a quadrivalent HPV vaccine, resulting in a greater averted cost for the bivalent vaccine, suggest researchers from Italy and Belgium. * The researchers used a prevalence-based model to evaluate the incidence of HPV-related lesions and associated costs averted with the use of a bivalent HPV-16/18 vaccine [Cervarix], compared with a quadrivalent HPV-6/11/16/18 vaccine [Gardasil]. The HPV-related lesions included in the study were abnormal Pap smear, cervical intraepithelial neoplasia (CIN), cervical cancer, and genital warts. The cost analysis was conducted from the Italian NHS perspective. The results of the study indicate that the bivalent vaccine would prevent more abnormal pap smears, cervical cancer, CIN1, and CIN2/3 lesions than the quadrivalent vaccine; the quadrivalent vaccine would prevent more genital warts cases than the bivalent vaccine. According to the results, the prevented cases of cervical cancer and genital warts associated with each vaccine would have the greatest effect on the total cost averted. The model estimated that the bivalent vaccine, compared with the quadrivalent vaccine, would result in an additional cost ** averted of €2 385 354 per year. * This study was funded by GlaxoSmithKline Biologicals ** 2010 values Capri S, et al. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles. Gynecologic Oncology : 18 Feb 2011. Available from: URL: http:// dx.doi.org/10.1016/j.ygyno.2011.01.029 803051432 1 PharmacoEconomics & Outcomes News 19 Mar 2011 No. 624 1173-5503/10/0624-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Post on 23-Dec-2016

214 views

Category:

Documents

1 download

Report

Download

Embed Size (px):

TRANSCRIPT

PharmacoEconomics & Outcomes News 624 - 19 Mar 2011

Bivalent HPV vaccine outshinesquadrivalent vaccine?

In Italy, a bivalent human papillomavirus (HPV)vaccine may be associated with a greater reduction inprecancerous and cervical cancer lesions than aquadrivalent HPV vaccine, resulting in a greater avertedcost for the bivalent vaccine, suggest researchers fromItaly and Belgium.*

The researchers used a prevalence-based model toevaluate the incidence of HPV-related lesions andassociated costs averted with the use of a bivalentHPV-16/18 vaccine [Cervarix], compared with aquadrivalent HPV-6/11/16/18 vaccine [Gardasil]. TheHPV-related lesions included in the study wereabnormal Pap smear, cervical intraepithelial neoplasia(CIN), cervical cancer, and genital warts. The costanalysis was conducted from the Italian NHSperspective.

The results of the study indicate that the bivalentvaccine would prevent more abnormal pap smears,cervical cancer, CIN1, and CIN2/3 lesions than thequadrivalent vaccine; the quadrivalent vaccine wouldprevent more genital warts cases than the bivalentvaccine. According to the results, the prevented cases ofcervical cancer and genital warts associated with eachvaccine would have the greatest effect on the total costaverted. The model estimated that the bivalent vaccine,compared with the quadrivalent vaccine, would result inan additional cost** averted of €2 385 354 per year.* This study was funded by GlaxoSmithKline Biologicals** 2010 values

Capri S, et al. Cost-consequences evaluation between bivalent and quadrivalentHPV vaccines in Italy: The potential impact of different cross-protection profiles.Gynecologic Oncology : 18 Feb 2011. Available from: URL: http://dx.doi.org/10.1016/j.ygyno.2011.01.029 803051432

GENIUS AGAIN OUTSHINES OTHERS - Genius Students … · GENIUS AGAIN OUTSHINES OTHERS ... Paras Kathuria Radhika Sachdeva Rahul ... Sidharth Thakur Prateek Sharma Vasavi Garg Nikita

Prophylactic Quadrivalent Human Papillomavirus (HPV) (Types 6, 11

Quadrivalent Meningococcal Vaccination of Adults: Phase ... · of an Investigational Conjugate Vaccine, MenACWY-CRM, with the Licensed Vaccine, Menactra Keith S. Reisinger,1* Roger

AIPO VFC PEDIATRIC INFLUENZA VACCINE 2020-2021 · NDC 49281-0420-50 Fluzone® Quadrivalent Sanofi Pasteur, Inc. 0.5 mL single-dose vial,10 pack NDC 49281-0420-10 FluLaval® Quadrivalent

Quadrivalent influenza vaccine developments · Selection of influenza B strain for vaccine From Belshe, Vaccine 2010;285:D45–53. Influenza Predominant lineage Mismatch season of

FLUZONEMD Haute Dose Quadrivalent

FLUZONE High-Dose Quadrivalent

FLULAVAL QUADRIVALENT - GSKpro

Presentation title, 32 ptsDengvaxia® (1) Mid-to-severe dengue fever vaccine PR5i DTP-HepB-Polio-Hib Pediatric hexavalent vaccine U.S. VaxiGrip® QIV IM (2) Quadrivalent inactivated

Product Monograph - Fluzone® Quadrivalent · Nursing Women. It is not known whether FLUZONE ® Quadrivalent is excreted in human milk. Caution must be exercised when FLUZONE ® Quadrivalent

Safety and Immunogenicity of Fluzone Quadrivalent Vaccine ...Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age Phase

influenza vacine Web viewThis trial compared the protective efficacy in older adults of a quadrivalent, recombinant influenza vaccine (RIV4) with a standard-dose, egg-grown, quadrivalent